• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

GHIT Fund renews support for DNDi drug discovery and early-stage development for leishmaniasis and Chagas disease

Additional JPY 955 million (EUR 7.4 million) in funding will support work to advance urgently needed medical innovation for millions of people affected by the two neglected tropical diseases

Home > Press releases

GHIT Fund renews support for DNDi drug discovery and early-stage development for leishmaniasis and Chagas disease

Additional JPY 955 million (EUR 7.4 million) in funding will support work to advance urgently needed medical innovation for millions of people affected by the two neglected tropical diseases

Lab equipment
Geneva, Switzerland — 18 May 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • 日本語

The Drugs for Neglected Diseases initiative (DNDi) welcomes renewed support from Japan’s Global Health Innovative Technology Fund (GHIT Fund) for its drug discovery and early-stage development programmes pursuing new drug candidates for the treatment of leishmaniasis and Chagas disease.

A major contributor to DNDi’s not-for-profit research and development (R&D) programmes since 2013, GHIT Fund will provide a total of JPY 955 million (EUR 7.4 million) in additional funding for four projects over the 2021-2023 period, each underpinned by vital collaborations between DNDi and its Japanese R&D partners.

‘These four new investments are a further testament to the critical, long-term support provided by the GHIT Fund, which enables DNDi and our Japanese partners from the pharmaceutical industry, research institutes, and academic institutions to discover and develop innovative new treatments for neglected patients,’ said Charles Mowbray, DNDi Discovery Director. ‘The world-leading R&D capabilities of our partners coupled with the GHIT Fund’s support for early-stage research are incredibly important, creating a special and unique environment for scientific innovation for global health. We believe that these newly supported projects will play a crucial part in the effort to develop new treatments for patients suffering from Chagas disease and leishmaniasis.’

Safer, simpler, more effective treatments for leishmaniasis and Chagas disease are urgently needed. Existing treatments for leishmaniasis can be painful, toxic, lengthy, and costly, and poorly adapted for use in the most affected communities. Treating leishmaniasis is also difficult because it depends on several factors, including the form of the disease, other co-existing infections, the parasite species, and different patient populations – as treatment responses differ by region. There are only two drugs available to treat Chagas disease, both discovered half a century ago. While effective for some patients, existing treatments last eight weeks and sometimes have serious side effects.

Projects in focus

Hit-to-lead development for visceral leishmaniasis and Chagas disease – with Mitsubishi Tanabe Pharma Corporation

A continuation of DNDi’s compound screening collaboration with Mitsubishi-Tanabe that succeeded in identifying promising T. cruzi and/or Leishmania active series, this project aims to identify at least one compound series that meets DNDi’s target candidate profiles for new chemical entities for leishmaniasis and Chagas disease. Efforts will focus on strengthening the early-stage R&D pipeline for the two diseases by providing new promising series that bolster the prospects for successful development of all-new treatments.

S07 lead optimization for visceral leishmaniasis – with Takeda Pharmaceutical Company Limited

This project originated from DNDi’s successful GHIT-funded NTD Drug Discovery Booster programme which, following further development in collaboration with Takeda, identified and advanced novel compounds against visceral leishmaniasis, resulting in the S07 lead chemical series of compounds that show promising efficacy and safety profiles. The collaboration will now support medicinal chemistry optimization for the S07 leads it has identified, with the aim of progressing at least one optimized lead to deliver a pre-clinical candidate compound for visceral leishmaniasis.

DNDI-6174 pre-clinical development for leishmaniasis – with Eisai Co., Ltd.

Emerging from the leishmaniasis L205 lead optimization series, DNDI-6174 presents a new mode of action to the leishmania portfolio as well as a low human dose prediction and a very promising safety margin. It was nominated as a pre-clinical candidate, and through this two-year project, DNDi and Eisai will collaborate to prepare the way for future Phase I clinical development in healthy human volunteers.

Screening for visceral leishmaniasis – with The University of Tokyo

The objective of this new collaboration is to screen the chemical library of the University of Tokyo’s Drug Discovery Initiative (DDI) against Leishmania donovani to identify hit series for progression as candidates for hit-to-lead optimization – the first GHIT-supported project screening a Japanese academic chemical library of this size and complexity. The project also aims to provide new information on antileishmanial modes of action and on the biology of Leishmania parasites while fostering collaboration and expertise in anti-leishmanial screening and validation in Japan. DNDi’s contribution to this project will be provided fully on an in-kind basis.

About leishmaniasis

Leishmaniasis is a neglected tropical disease that threatens an estimated one billion people worldwide. It is a complex disease that presents in several forms – visceral, cutaneous, mucocutaneous, and post-kala-azar dermal leishmaniasis – and is caused by 20 different Leishmania parasite species. An estimated 700,000 to 1 million new cases of leishmaniasis occur annually, with 20,000 to 30,000 deaths.

About Chagas disease

Caused by the protozoan Trypanosoma cruzi and transmitted by biting insects known as ‘kissing bugs’, Chagas disease is endemic in 21 countries in the Americas and is also present in Europe, Japan, and Australia. Chagas affects approximately 6-7 million people, with 30,000 new cases and 14,000 deaths per year. As people typically show no symptoms for many years, most are unaware they have the disease. Up to a third of people with Chagas will eventually suffer heart damage that can lead to progressive heart failure or sudden death. Chagas kills more people in Latin America each year than any other parasitic disease, including malaria.

About the Drugs for Neglected Diseases initiative (DNDi)

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating a clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered eight new treatments to date, including new drug combinations for visceral leishmaniasis (kala-azar), two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Press contact

Frédéric Ojardias
fojardias@dndi.org
Phone: +41 79 431 6216

Photo credit: Vinicius Berger-DNDi

Drug discovery Funding Translational research Chagas disease Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Centre of Excellence in India
News
14 Sep 2023

DNDi’s Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India

Delali Attip
Press releases
6 Sep 2023

Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director

Viewpoints
5 Sep 2023

Africa should bolster research into climate-sensitive diseases

Context
Prof. Sam Kariuki, DNDi Eastern Africa Director and Leonard Ithau, Rotary International District 9212 District Governor shaking hands
News
29 Aug 2023

DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa

Mother and child in a hospital
Viewpoints
24 Aug 2023

A drug development model for the diseases the world forgot

Africa Arguments
Statements
21 Aug 2023

DNDi urges G20 to operationalize equity in response to major global health challenges and priorities

Man looking into a microscope
Press releases
31 Jul 2023

Certara and DNDi partnering to fast-track data submissions and accelerate drug approvals for neglected patients

DNDi Prof. Fahal Interview 2023 Cover Image
Videos
25 Jul 2023

Prof. Fahal On The 20 Years of Innovating Together In Helping Mycetoma Patients

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo